As we navigate these challenging times, Certara is providing the drug development community with recent and relevant information regarding COVID-19 and facilitating professional development with on-demand resources. If you have any questions or comments, please contact us by filling out the form below.

Certara is providing support to several COVID-19 projects, including:

  • Evidence Generation as the scientific lead for a global Healthcare Worker Registry for COVID-19
  • Simulation Modeling to support vaccine and therapeutics development
  • Regulatory Consulting in preparation for studies evaluating COVID-19 sample collection techniques
  • Ultra-rapid Regulatory Operations Submission Support for pre-IND/IND submissions and CMC amendments
  • Regulatory Writing
  • Pricing and Access Analysis for COVID-19 vaccine candidates

Please contact us today and let us know how we can help advance your critical therapeutics and vaccines.


Certara’s Commitment

Certara recognizes the impact COVID-19 is having on our daily personal and business lives. We continue to support our customers' discovery and drug development efforts during this time with scientific informatics, modelling and simulation, and regulatory software tools and platforms to inform, improve and accelerate the process of bringing therapies to patients.

Business Continuity and Support

We continue to commit to maintaining business continuity of our technology and support efforts. Support channels continue to be staffed globally providing 24/5 coverage to ensure rapid and meaningful responsiveness. Our remote and dispersed development and implementation staff and infrastructure and our proven processes and practices allow us to continue to operate be productive, and stay connected to our customers.



Model-based meta-analysis for comparative efficacy and safety of therapeutics for COVID-19

COVID-19: Building for Today
and Tomorrow – Therapeutic Considerations for Children
and Pregnant Women

Archived Webinars

Model-informed Drug Repurposing - Applications for COVID-19
Coming Soon

Considerations for Management of Clinical Trials and Regulatory Filing Strategy in Light of COVID-19
Watch Now

Accelerating Therapeutics for COVID-19
Watch Now

COVID-19: Building for Today
and Tomorrow – Therapeutic Considerations for Children
and Pregnant Women
Watch Now

COVID-19 Response: New Opportunities & Implications for the Future of Drug Development in Emerging Economies
Recording Coming Soon

Scientific Resources

Dosing will be a key success factor in repurposing antivirals for COVID‐19
Read Now

Optimizing COVID‐19 candidate therapeutics: Thinking Without Borders
Read Now

Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load
Read Now

Structural Basis for Potent
10-4: How to Reopen the Economy by Exploiting the Coronavirus’s Weak Spot
Read Now

Doctors keep discovering new
ways the coronavirus attacks the body
Read Now

Routine vaccinations for U.S. children have plummeted during
the Covid-19 pandemic
Read Now

An emerging antiviral takes aim at COVID-19
Read Now

Loss of Smell, Taste May Be Reliable Predictor of COVID-19: Study
Read Now

Human trials begin despite warnings about Monash' COVID-19 head lice study
Read Now

Regulatory Resources

EMA Offers Guidance on Conducting Trials During the COVID-19 Pandemic
Read Now

FDA Guidance on Conduct of
Clinical Trials of Medical Products During
COVID-19 Pandemic
Read Now

Call to pool research resources into
large multi-centre, multi-arm clinical trials to generate sound evidence on COVID-19 treatments
Read Now

Clinical Trials During COVID-19: Updates From FDA, MHRA and TGA
Read Now


Additional Resources Available

In order to facilitate a productive work environment during this time, the following resources are available:

  • Certara will be offering a temporary Phoenix license key to anyone affected by working remotely. Email [email protected] for more information.
  • On-demand webinars covering scientific use cases using Certara software are also available to view at any time. Visit Certara/Scientific Resources to access.
  • To view Certara BaseCase, an interactive communication platform, educational resources click here.

Please do not hesitate to contact your Account Manager or [email protected] with any questions or concerns.


Frequently Asked Questions

  • Are Certara staff now working remotely?
    Yes, all of our employees are working remotely. As a global company with almost 40 offices, we are well set up with a robust IT infrastructure.
  • Are there any Certara offices that are open?
    Our physical locations are currently not available for access by visitors. But, we remain open for business, and we are still working hard to deliver on our commitments to you, our clients.
  • What are Certara’s business continuity plans?
    We have reliable safeguards and robust business continuity plans in place and in operation currently. If you need additional information, please contact your project lead or account manager.
  • What is Certara doing about COVID-19?
    Our top priority is the safety, health, and wellness of our employees and customers. We are listening to them and creating flexible solutions to support them in this challenging time. Remote working resources, as well as employee assistance programs, are available worldwide. We are also partnering with several organizations on developing therapies for COVID-19.
  • What resources are available from Certara for professional development?
    We offer free scientific webinars which are presented live but also available as recordings. You can find recent webinars to enjoy anytime and anywhere here: At Certara University, we also offer a wide variety of virtual learning options and our certification program.

Additional text can go here...